Literature DB >> 16545752

Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism.

Anette Schrag1, Jonathan M Schott.   

Abstract

In this review we discuss the epidemiological, clinical, and genetic characteristics of early-onset parkinsonism, defined as parkinsonism starting before age 40 (sometimes 50) years. Juvenile parkinsonism is very rare and is the result of various secondary or genetic causes. In patients with onset at or above age 21 years, secondary causes require exclusion but are rare; most cases with a fairly pure parkinsonian syndrome (eg, young-onset Parkinson's disease; YOPD) are due to typical Lewy-body Parkinson's disease or, less commonly, genetic causes. In comparison with patients with late-onset disease, most patients with YOPD progress more slowly in terms of motor features and have a longer disease course with preservation of cognitive function, but typically develop motor fluctuations and dyskinesias earlier. Patients with YOPD generally experience a greater effect in their lives than those with late onset, with poorer social adjustment, higher rates of depression, and lower quality of life. Management of YOPD must therefore aim to maintain occupational, social, and daily functioning, while delaying or ameliorating motor complications of treatment, providing psychological support, and, where possible, preventing psychiatric complications including depression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545752     DOI: 10.1016/S1474-4422(06)70411-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  88 in total

Review 1.  Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Authors:  Teri R Thomsen; Robert L Rodnitzky
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

2.  CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.

Authors:  David A Loeffler; Lynnae M Smith; Mary P Coffey; Jan O Aasly; Peter A LeWitt
Journal:  J Neural Transm (Vienna)       Date:  2015-11-03       Impact factor: 3.575

3.  Patterns of striatal functional connectivity differ in early and late onset Parkinson's disease.

Authors:  Yanbing Hou; Jing Yang; Chunyan Luo; Ruwei Ou; Wei Song; Wanglin Liu; Qiyong Gong; Huifang Shang
Journal:  J Neurol       Date:  2016-07-09       Impact factor: 4.849

4.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

5.  Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.

Authors:  Elise Caccappolo; Roy N Alcalay; Helen Mejia-Santana; Ming-X Tang; Brian Rakitin; Llency Rosado; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Howard F Andrews; Cheryl Waters; Stanley Fahn; Lucien J Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Brad Hiner; Andrew D Siderowf; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Ruth Ottman; Lorraine N Clark; Karen S Marder
Journal:  J Int Neuropsychol Soc       Date:  2010-11-24       Impact factor: 2.892

6.  Phenotype analysis in patients with early onset Parkinson's disease with and without parkin mutations.

Authors:  Hee Jin Kim; Han-Joon Kim; Jee-Young Lee; Ji Young Yun; So Yeon Kim; Sung Sup Park; Beom S Jeon
Journal:  J Neurol       Date:  2011-05-29       Impact factor: 4.849

7.  Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Ming X Tang; Brian Rakitin; Llency Rosado; Barbara Ross; Miguel Verbitsky; Sergey Kisselev; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline Tanner; Susan F Mickel; Howard F Andrews; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Ruth Ottman; Lorraine N Clark; Karen S Marder; Elise Caccappolo
Journal:  J Clin Exp Neuropsychol       Date:  2010-02-24       Impact factor: 2.475

Review 8.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

9.  Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.

Authors:  Maria Jose Catalan; Jose Antonio Molina-Arjona; Pablo Mir; Esther Cubo; Jose Matias Arbelo; Pablo Martinez-Martin
Journal:  J Neurol       Date:  2018-03-20       Impact factor: 4.849

Review 10.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.